RxDoctor Payments Data

Hirsch Mehta, MD

Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1407099799

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $422,524 of the $494,085 with a category attached, or 85.5%. It is spread thinly across 50 manufacturers, the largest accounting for just 23.5%. Among advanced heart failure and transplant cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$494,085in general payments, 2019–2025

Across 1,246 payments — averaging $396.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$116K
  • Merck$68K
  • Boehringer Ingelheim$56K
  • Boston Scientific$37K
  • Alnylam Pharmaceuticals Inc.$35K
  • E.r. Squibb & Sons, L.L.C.$30K
  • plus $152K from 44 others
$351,114in research payments, 2019–2025

Across 67 payments — averaging $5240.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$169K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$75K
  • Boehringer Ingelheim International GmbH$59K
  • Janssen Research & Development, LLC$23K
  • Amgen$19K
  • Merck$6K

What the payments were for

  • Consulting fees$35,8867%
  • Speaking & faculty fees$422,52486%
  • Travel & lodging$16,6673%
  • Food & beverage$18,9044%
  • Education$1060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$494,085 in reported general payments places this provider in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$544,426
Medicare patients
960
Services billed
5,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan51$711,957
AdempasRiociguat54$686,572
VyndamaxTafamidis26$642,966
UptraviSelexipag33$637,418
CamzyosMavacamten51$411,401
EliquisApixaban174$236,294
EntrestoSacubitril/Valsartan69$116,020
JardianceEmpagliflozin78$111,833
XareltoRivaroxaban29$46,010
FarxigaDapagliflozin Propanediol23$37,609
Repatha SureclickEvolocumab20$27,271
VascepaIcosapent Ethyl26$18,464
Praluent PenAlirocumab12$12,606
Rosuvastatin Calcium431$9,755
Repatha PushtronexEvolocumab11$8,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$115,866$1,349,37584 claims
PfizerVyndamax, Eliquis$22,516$879,261200 claims
BayerAdempas$29,782$686,57254 claims
E.r. Squibb & Sons, L.L.C.Camzyos$29,976$411,40151 claims
NovartisEntresto$418$116,02069 claims
Boehringer IngelheimJardiance$55,734$111,83378 claims
Johnson & JohnsonXarelto$249$46,01029 claims
AstraZenecaFarxiga$22,863$37,60923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →